Replay available

Acurx Pharmaceuticals, Inc. (ACXP) Q1 2025 Earnings Call

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) Q1 2025 earnings conference call, held 2025-05-13. Replay captured from the company's public earnings webcast.

Tue, May 13, 2025 at 8:00 AMendedReplay
Acurx Pharmaceuticals, Inc. (ACXP) Q1 2025 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Rob Schaller

Chief Financial Officer

David Lucci

President and Chief Executive Officer

Joanne Leon

Analyst, Maxim Group (on behalf of Jason McCarthy)

James Malloy

Analyst, Alliance Global Partners

Replay transcript excerpt

and welcome to the Accurate Pharmaceuticals first quarter 2025 financial results and business update. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press bar zero on your telephone keypad. As a reminder, this conference is being recorded. I would now like to turn the call over to your host, Rob Schaller, Chief Financial Officer of Accurate Pharmaceuticals. Thank you. You may begin. Thank you, Melissa. Good morning, and welcome to our call. This morning, we issued a press release providing financial results and company highlights for the first quarter of 2025, which is available on our website at accorexpharma.com. Joining me today is David Lucci, President and CEO of Accorex, who will give a corporate update and outlook. Following that, I'll provide some highlights of the financials from the first quarter ended March 31, and then turn the call back over to Dave for closing remarks. As a reminder, during today's call, we'll be making certain forward-looking statements which are based on current information, assumptions, estimates, and projections about future events that are subject to change and involve a number of risks and uncertainties, that may cause actual results to differ materially in those contained in the forward-looking statements. Investors should consider these risks and other information described in our filings with the Securities and Exchange Commission, including our quarterly report on Form 10-Q, which we filed yesterday, Monday, May 12, 2025. You are cautioned not to place undue reliance on these forward-looking statements An ACREX disclaims any obligation to update such statements at any time in ...

More from Acurx Pharmaceuticals, Inc.